Abstract:Background and purpose:Promoter methylation ofPCDH10, a gene encoding protocadherin 10, has been found to be correlated to poor prognosis in gastric cancer (GC) patients. However, the relationship between the expression of PCDH10 and prognosis in GC remained unknown. This study aimed to explore the relationship be-tween the expression of PCDH10 and clinicopathological features and prognosis of GC, and to identify biomarker for predictions of recurrence and survival of GC.Methods:mRNA expressions of PCDH10 in 115 pairs of GC tissues and adjacent normal tissues were detected by real-time lfuorescence quantitative polymerase chain reaction (RTFQ-PCR). The correlation between PCDH10 expression level and clinicopathological features and prognosis of GC was analyzed. Prediction models for 5-year recurrence and 5-year survival were established using logistic regression method.Results:Progression-free survival (PFS) and overall survival (OS) were signiifcantly prolonged in patients with PCDH10 low expression compared to patients without PCDH10 low expression (P=0.046 andP=0.033 respectively). PCDH10 low expression signiifcantly correlated with less lymph node metastasis (P=0.001) and earlier TNM staging (P=0.001), and was more common in female than in male (P=0.040). The mRNA expression of PCDH10 did not correlate with age, Lauren classiifcation, T stage, neural invasion or vascular invasion. Univariate Cox analysis showed Lauren classiifca-tion, T stage, N stage, M stage and PCDH10 expression signiifcantly correlated with PFS and OS. Logistic regression models for the prediction of 5-year recurrence or 5-year survival based on clinicopathological features included Lauren classiifcation, T stage, N stage and M stage as variables. Logistic regression models for the prediction of 5-year recur-rence or 5-year survival based on PCDH10 expression included Lauren classiifcation, T stage, M stage and PCDH10 expression level but not N stage as variables. The models based on PCDH10 expression had the same effciencies as models based on clinical parameters in predicting 5-year recurrence or 5-year survival for GC patients.Conclusion:PCDH10 low expression correlated with better prognosis, less lymph node metastasis and earlier TNM stage in GC patients. Low expression of PCDH10 may be a biomarker of better survival for GC patients. Logistic regression model based on PCDH10 mRNA expression may serve as a prediction model when patients have unknown lymph node metas-tasis status.

Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

PCDHGA9 acts as a tumor suppressor to induce tumor cell apoptosis and autophagy and inhibit the EMT process in human gastric cancer

Nuclear translocation of cleaved PCDH9 impairs gastric cancer metastasis by downregulating CDH2 expression

Downregulation of PCDH9 predicts prognosis for patients with glioma.

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

Correlation between mRNA expression of protocadherin-10 and prognosis in gastric cancer

Protocadherin 17 Acts As a Tumour Suppressor Inducing Tumour Cell Apoptosis and Autophagy, and is Frequently Methylated in Gastric and Colorectal Cancers

Protocadherin-8 Promotes Invasion and Metastasis Via Laminin Subunit Γ2 in Gastric Cancer.

Aberrant Expression of PHLPP1 Correlates with Poor Prognosis in Patients with Gastric Cancer

PCDH20 acts as a tumour-suppressor gene through the Wnt/β-catenin signalling pathway in hypopharyngeal squamous cell carcinoma

PCDHGA10 as a potential prognostic biomarker and correlated with immune infiltration in gastric cancer

Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma

Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patients.

Lower Expression of PH Domain Leucine-Rich Repeat Protein Phosphatase 1 (PHLPP1) Association with Poor Prognosis of Gastric Cancer.

Phosphoglycerate Dehydrogenase is a Novel Predictor for Poor Prognosis in Gastric Cancer.

Pcdh9 Acts As A Tumor Suppressor Inducing Tumor Cell Arrest at G(0)/G(1) Phase and is Frequently Methylated in Hepatocellular Carcinoma

Characterizing the Role of PCDH9 in the Regulation of Glioma Cell Apoptosis and Invasion

Methylation of the PCDH8 （Protocadherin-8） Gene in Gastric Cancer

High Expression of PABPC1 Predicts Worse Survival of Gastric Cancer Patients

Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer